The cost of cancer care: There is more than one elephant in the room

ONCOLOGY (United States)

Volumn 26, Issue 10, 2012, Pages

  de Souza, Jonas A ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; SIPULEUCEL T;

AGING; CANCER SURVIVAL; CANCER THERAPY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; DRUG UTILIZATION; EVIDENCE BASED MEDICINE; GASTROINTESTINAL STROMAL TUMOR; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEDICARE; NOTE; PRESCRIPTION; PROSTATE CANCER; REIMBURSEMENT; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

EID: 84874596702     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (12)

1. IMS Institute for Healthcare Informatics: The use of medicine in the United States: review of 2011. April 2012. Available from: http://www.imshealth.com/ims/Global/Content/Insights/IMS Institute for Healthcare Informatics/IHII_Medicines_in_U.S_Report_2011.pdf. Accessed September 20, 2012.
2. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24:3089-94.
3. Centers for Medicare and Medicaid Services. Annual report of the Boards of Trustees of the Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds, 2010. Available from: http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/ReportsTrustFunds/downloads/. Accessed September 20, 2012.
4. Danzon PM, Taylor E. Drug pricing and value in oncology. Oncologist. 2011;15(suppl 1):24-31.
5. Jacobson M, OMalley AJ, Earle CC, et al. Does reimbursement influence chemotherapy treatment for cancer patients? Health Aff (Millwood). 2006;25:437-43.
6. Willey VJ, Pollack MF, Lawless GD. Oncology health care and patient out-of-pocket cost trends in a commercially insured population. J Clin Oncol. 2008;26(May 20 suppl):abstr 6503.
7. Americas Health Insurance Plans (AHIP) Center for Policy and Research. 2012 HSA census. Available from: http://www.ahip.org/HSA2012. Accessed September 20, 2012.
8. Weaver KE, Rowland JH, Belizzi KM, et al. Forgoing medical care because of cost: assessing disparities in healthcare access among cancer survivors living in the United States. Cancer. 2010;116:3493-504.
9. Bernard DSM, Farr SL, Fang Z. National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008. J Clin Oncol. 29:2821-6.
10. Ramsey SD. How should we pay the piper when hes calling the tune? On the long-term affordability of cancer care in the United States. J Clin Oncol. 2007;25:175-9.
11. Neugut AI, Becker DJ, Buono D, et al. Off-label and approved use of bevacizumab in elderly patients with colon cancer. J Clin Oncol. 2010;28(suppl): abstr e14038.
12. de Souza JA, Polite BN, Zhu S, et al. Utilization and costs of non-evidence-based (non-EBM) antineoplastic agents in patients with metastatic colon cancer (mCC). J Clin Oncol. 2011;29(suppl): abstr 6002.